Actavis Group PTC ehf (1) - søkeresultat

zopiclone actavis 7.5 mg

actavis group ptc ehf - zopiklon - tablett, filmdrasjert - 7.5 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

imatinib actavis

actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. effekten av imatinib på utfallet av bein marg transplantasjon har ikke fastsatt. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. erfaring med imatinib hos pasienter med mds/mpd forbundet med pdgfr gene re-ordninger er svært begrenset. det er ingen kontrollerte studier som viser en klinisk nytte eller økt overlevelse for disse sykdommer.

Den europeiske union - norsk - EMA (European Medicines Agency)

sildenafil actavis

actavis group ptc ehf - sildenafil - erektil dysfunksjon - urologika - behandling av menn med erektil dysfunksjon, som er manglende evne til å oppnå eller opprettholde en penis ereksjon tilstrekkelig for tilfredsstillende seksuell ytelse. for sildenafil actavis å være effektiv, seksuell stimulering er nødvendig.

Norge - norsk - Statens legemiddelverk

oxycodone actavis 20 mg

actavis group ptc ehf - oksykodonhydroklorid - kapsel, hard - 20 mg

Norge - norsk - Statens legemiddelverk

oxycodone actavis 5 mg

actavis group ptc ehf - oksykodonhydroklorid - kapsel, hard - 5 mg

Norge - norsk - Statens legemiddelverk

oxycodone actavis 10 mg

actavis group ptc ehf - oksykodonhydroklorid - kapsel, hard - 10 mg

Norge - norsk - Statens legemiddelverk

ramipril actavis 5 mg

actavis group ptc ehf (1) - ramipril - tablett - 5 mg